221 related articles for article (PubMed ID: 30089721)
1. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Lee DI; Zhu G; Sasaki T; Cho GS; Hamdani N; Holewinski R; Jo SH; Danner T; Zhang M; Rainer PP; Bedja D; Kirk JA; Ranek MJ; Dostmann WR; Kwon C; Margulies KB; Van Eyk JE; Paulus WJ; Takimoto E; Kass DA
Nature; 2015 Mar; 519(7544):472-6. PubMed ID: 25799991
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.
Kim GE; Kass DA
Handb Exp Pharmacol; 2017; 243():249-269. PubMed ID: 27787716
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.
Diederen RM; La Heij EC; Markerink-van Ittersum M; Kijlstra A; Hendrikse F; de Vente J
Br J Ophthalmol; 2007 Mar; 91(3):379-84. PubMed ID: 16943225
[TBL] [Abstract][Full Text] [Related]
5. Cyclic GMP-dependent signaling in cardiac myocytes.
Takimoto E
Circ J; 2012; 76(8):1819-25. PubMed ID: 22785374
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice.
da Silva FH; Pereira MN; Franco-Penteado CF; De Nucci G; Antunes E; Claudino MA
Int J Impot Res; 2013; 25(2):69-73. PubMed ID: 23034509
[TBL] [Abstract][Full Text] [Related]
7. CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure.
Richards DA; Aronovitz MJ; Liu P; Martin GL; Tam K; Pande S; Karas RH; Bloomfield DM; Mendelsohn ME; Blanton RM
Circ Heart Fail; 2021 Jan; 14(1):e007300. PubMed ID: 33464954
[TBL] [Abstract][Full Text] [Related]
8. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental HeartĀ Failure.
Scott NJA; Rademaker MT; Charles CJ; Espiner EA; Richards AM
J Am Coll Cardiol; 2019 Aug; 74(7):889-901. PubMed ID: 31416533
[TBL] [Abstract][Full Text] [Related]
10. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
12. Gastrodin promotes hippocampal neurogenesis via PDE9-cGMP-PKG pathway in mice following cerebral ischemia.
Xiao H; Jiang Q; Qiu H; Wu K; Ma X; Yang J; Cheng O
Neurochem Int; 2021 Nov; 150():105171. PubMed ID: 34419525
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors.
Karami-Tehrani F; Moeinifard M; Aghaei M; Atri M
Arch Med Res; 2012 Aug; 43(6):470-5. PubMed ID: 22960860
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells.
Yao J; Hiramatsu N; Zhu Y; Morioka T; Takeda M; Oite T; Kitamura M
J Am Soc Nephrol; 2005 Jan; 16(1):58-67. PubMed ID: 15537869
[TBL] [Abstract][Full Text] [Related]
15. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of type 5 phosphodiesterase counteracts Ī²2-adrenergic signalling in beating cardiomyocytes.
Isidori AM; Cornacchione M; Barbagallo F; Di Grazia A; Barrios F; Fassina L; Monaco L; Giannetta E; Gianfrilli D; Garofalo S; Zhang X; Chen X; Xiang YK; Lenzi A; Pellegrini M; Naro F
Cardiovasc Res; 2015 Jun; 106(3):408-20. PubMed ID: 25852085
[TBL] [Abstract][Full Text] [Related]
17. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.
Zhang M; Takimoto E; Lee DI; Santos CX; Nakamura T; Hsu S; Jiang A; Nagayama T; Bedja D; Yuan Y; Eaton P; Shah AM; Kass DA
Circulation; 2012 Aug; 126(8):942-51. PubMed ID: 22829024
[TBL] [Abstract][Full Text] [Related]
18. Role of PDE9 in Cognition.
Dorner-Ciossek C; Kroker KS; Rosenbrock H
Adv Neurobiol; 2017; 17():231-254. PubMed ID: 28956335
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Stehlik J; Movsesian MA
Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
[TBL] [Abstract][Full Text] [Related]
20. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
